The Medicines
Parsippany
About The Medicines
The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R) (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has two products in late stage development: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. The Company's pipeline also includes a serine protease inhibitor, CU2010, in early-stage development.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 1,001 – 5,000
- Estimated revenue: $1K – $10K
- Total funding: $400.0M
- Funding stage: M&A
- Last round: Post-IPO Debt (Jan 2015)
- Ticker: nasdaq:MDCO
- Website: themedicinescompany.com
- Phone: (973) 290-6000
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/the-medicines-2805828 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.